Pharmacovigilance principles US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Pharmacovigilance principles. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pharmacovigilance principles US Medical PG Question 1: A 14-year-old boy is brought to the emergency department because of a 4-hour history of vomiting, lethargy, and confusion. Three days ago, he was treated with an over-the-counter medication for fever and runny nose. He is oriented only to person. His blood pressure is 100/70 mm Hg. Examination shows bilateral optic disc swelling and hepatomegaly. His blood glucose concentration is 65 mg/dL. Toxicology screening for serum acetaminophen is negative. The over-the-counter medication that was most likely used by this patient has which of the following additional effects?
- A. Increased partial thromboplastin time
- B. Decreased uric acid elimination
- C. Decreased expression of glycoprotein IIb/IIIa
- D. Irreversible inhibition of ATP synthase
- E. Irreversible inhibition of cyclooxygenase-1 (Correct Answer)
Pharmacovigilance principles Explanation: ***Irreversible inhibition of cyclooxygenase-1***
- The patient's presentation is classic for **Reye syndrome** (vomiting, lethargy, confusion, cerebral edema with optic disc swelling, hepatomegaly, hypoglycemia) following recent viral illness treated with OTC medication
- **Aspirin** is strongly associated with Reye syndrome in children with viral infections and should be avoided in this population
- The "additional effect" of aspirin is its mechanism of action: **irreversible acetylation and inhibition of COX-1 and COX-2**
- This irreversible COX inhibition also explains aspirin's antiplatelet effects (via inhibition of thromboxane A2 synthesis) and anti-inflammatory properties
*Increased partial thromboplastin time*
- PTT measures the intrinsic and common coagulation pathways and is prolonged by **heparin** or clotting factor deficiencies
- Aspirin affects **platelet function** (prolonging bleeding time), not the coagulation cascade measured by PTT
- While Reye syndrome can cause coagulopathy from liver dysfunction, increased PTT is not a direct pharmacologic effect of aspirin
*Decreased uric acid elimination*
- **Low-dose aspirin** (<2 g/day) can decrease renal uric acid excretion and may precipitate gout
- While this is true, it is not the primary or most clinically relevant "additional effect" in this context
- High-dose aspirin actually increases uric acid excretion (uricosuric effect)
*Decreased expression of glycoprotein IIb/IIIa*
- This is the mechanism of **GP IIb/IIIa inhibitors** (abciximab, eptifibatide, tirofiban), not aspirin
- Aspirin inhibits platelet aggregation by preventing thromboxane A2 synthesis, not by affecting GP IIb/IIIa expression
- These are IV antiplatelet agents used in acute coronary syndromes, not OTC medications
*Irreversible inhibition of ATP synthase*
- This is not a mechanism of aspirin or other common OTC fever/cold medications
- While Reye syndrome involves mitochondrial dysfunction, aspirin does not directly inhibit ATP synthase
- The mitochondrial injury in Reye syndrome is likely multifactorial
Pharmacovigilance principles US Medical PG Question 2: A researcher is trying to determine whether a newly discovered substance X can be useful in promoting wound healing after surgery. She conducts this study by enrolling the next 100 patients that will be undergoing this surgery and separating them into 2 groups. She decides which patient will be in which group by using a random number generator. Subsequently, she prepares 1 set of syringes with the novel substance X and 1 set of syringes with a saline control. Both of these sets of syringes are unlabeled and the substances inside cannot be distinguished. She gives the surgeon performing the surgery 1 of the syringes and does not inform him nor the patient which syringe was used. After the study is complete, she analyzes all the data that was collected and performs statistical analysis. This study most likely provides which level of evidence for use of substance X?
- A. Level 3
- B. Level 1 (Correct Answer)
- C. Level 4
- D. Level 5
- E. Level 2
Pharmacovigilance principles Explanation: ***Level 1***
- The study design described is a **randomized controlled trial (RCT)**, which is considered the **highest level of evidence (Level 1)** in the hierarchy of medical evidence.
- Key features like **randomization**, **control group**, and **blinding (double-blind)** help minimize bias and strengthen the validity of the findings.
*Level 2*
- Level 2 evidence typically comprises **well-designed controlled trials without randomization** (non-randomized controlled trials) or **high-quality cohort studies**.
- While strong, they do not possess the same level of internal validity as randomized controlled trials.
*Level 3*
- Level 3 evidence typically includes **case-control studies** or **cohort studies**, which are observational designs and carry a higher risk of bias compared to RCTs.
- These studies generally do not involve randomization or intervention assignment by the researchers.
*Level 4*
- Level 4 evidence is usually derived from **case series** or **poor quality cohort and case-control studies**.
- These studies provide descriptive information or investigate associations without strong control for confounding factors.
*Level 5*
- Level 5 evidence is the **lowest level of evidence**, consisting of **expert opinion** or **animal research/bench research**.
- This level lacks human clinical data or systematic investigative rigor needed for higher evidence levels.
Pharmacovigilance principles US Medical PG Question 3: A pharmaceutical company conducts a randomized clinical trial to demonstrate that their new anticoagulant drug, Aclotsaban, prevents more thrombotic events following total knee arthroplasty than the current standard of care. A significant number of patients are lost to follow-up, and many fail to complete treatment according to the study arm to which they were assigned. Despite these protocol deviations, the results for the patients who completed the course of Aclotsaban are encouraging. Which of the following analytical approaches is most appropriate for the primary analysis to establish the efficacy of Aclotsaban?
- A. Intention-to-treat analysis (Correct Answer)
- B. Sub-group analysis
- C. Per-protocol analysis
- D. As-treated analysis
- E. Non-inferiority analysis
Pharmacovigilance principles Explanation: ***Intention-to-treat analysis***
- **Intention-to-treat (ITT) analysis** is the gold standard for the **primary analysis in superiority trials** and includes all patients in the groups to which they were originally randomized, regardless of protocol deviations, loss to follow-up, or treatment discontinuation.
- ITT preserves **randomization balance**, prevents bias from selective dropout (patients may drop out due to adverse effects or lack of efficacy), and provides a **conservative, realistic estimate** of treatment effect in actual clinical practice.
- For **regulatory approval and establishing efficacy**, ITT is the most appropriate primary analysis method even when dropout rates are high, as it maintains the integrity of the randomized comparison.
*Per-protocol analysis*
- **Per-protocol analysis** includes only patients who completed the study exactly as planned without protocol deviations.
- While the encouraging results in completers are noted, per-protocol analysis can **introduce significant bias** by excluding patients who dropped out due to adverse events or lack of efficacy, potentially **overestimating treatment benefit**.
- Per-protocol is typically used as a **secondary/supportive analysis**, not the primary method for establishing superiority.
*As-treated analysis*
- **As-treated analysis** categorizes patients according to the treatment they actually received rather than their randomized assignment.
- This violates the principle of randomization and can introduce **confounding bias**, as actual treatment received may be influenced by prognostic factors.
*Sub-group analysis*
- **Sub-group analysis** evaluates treatment effects within specific patient subsets.
- This is **hypothesis-generating** rather than confirmatory and increases the risk of false-positive findings (multiple comparisons problem) unless pre-specified in the protocol.
*Non-inferiority analysis*
- **Non-inferiority analysis** tests whether a new treatment is not worse than control by more than a pre-specified margin.
- The goal here is to demonstrate **superiority** (better than standard care), not non-inferiority, making this approach inappropriate.
Pharmacovigilance principles US Medical PG Question 4: A 62-year-old man comes to his primary care physician with a 3-month history of insomnia and severe work anxiety. He says that he is unable to retire because he has no financial resources; however, the stress level at his work has been causing him to have worsening performance and he is afraid of being fired. He thinks that he would be able to resume work normally if he was able to decrease his level of anxiety. His physician prescribes him a trial 1-month regimen of benzodiazepine therapy and schedules a follow-up appointment to see whether this treatment has been effective. Three weeks later, the patient's wife calls and says "My husband was fired from work and it's your fault for prescribing that medication! I know he must have been taking too much of that drug. Don't you know that he had a horrible problem with drug abuse in his 30s?" Which of the following is the most appropriate first action for the physician to take?
- A. Discharge the patient for inappropriate use of medication
- B. Contact the physician's medical practice insurance company regarding a potential claim
- C. Refer the patient to a substance abuse program
- D. Contact the patient directly to discuss the situation (Correct Answer)
- E. Inform the patient's wife that patient information cannot be disclosed to her due to HIPAA
Pharmacovigilance principles Explanation: ***Contact the patient directly to discuss the situation***
- The physician's immediate priority is to address the patient's well-being and medication use directly with the patient, as the patient-doctor relationship is paramount and confidential.
- This allows the physician to gather information directly from the patient, assess the current situation, and plan appropriate next steps, which may include medication adjustment, referral, or relapse prevention depending on the patient's account.
*Discharge the patient for inappropriate use of medication*
- Discharging the patient based solely on a third-party report, especially without direct communication with the patient, would be premature and could be interpreted as **patient abandonment**.
- This action does not prioritize the patient's immediate medical and psychological needs and could worsen their situation by removing them from care.
*Contact the physician's medical practice insurance company regarding a potential claim*
- While potential legal implications exist, contacting the insurance company is not the **first and most appropriate medical action** to take.
- The immediate priority is the patient's health and safety, and managing potential legal risks can be addressed after ensuring the patient's well-being.
*Refer the patient to a substance abuse program*
- Although the patient's history and the wife's concerns suggest a potential for substance abuse, a direct referral without first assessing the patient and confirming misuse would be premature.
- The physician needs to **personally evaluate the patient** to determine the appropriate course of action, which might include such a referral, but it shouldn't be the very first step based on indirect information.
*Inform the patient's wife that patient information cannot be disclosed to her due to HIPAA*
- While the physician can listen to the wife's concerns (HIPAA does not prohibit receiving information from third parties), the physician **cannot discuss the patient's care or confirm treatment details** without the patient's authorization.
- However, simply informing the wife about confidentiality restrictions without taking action to contact and assess the patient is not the most appropriate first step—the priority is patient care, not just explaining privacy rules.
Pharmacovigilance principles US Medical PG Question 5: After the administration of an erroneous dose of intravenous phenytoin for recurrent seizures, a 9-year-old girl develops bradycardia and asystole. Cardiopulmonary resuscitation was initiated immediately. After 15 minutes, the blood pressure is 120/75 mm Hg, the pulse is 105/min, and the respirations are 14/min and spontaneous. She is taken to the critical care unit for monitoring and mechanical ventilation. She follows commands but requires sedation due to severe anxiety. Which of the following terms most accurately describes the unexpected occurrence in this patient?
- A. Active error
- B. Sentinel event (Correct Answer)
- C. Near miss
- D. Latent error
- E. Adverse event
Pharmacovigilance principles Explanation: ***Sentinel event***
- A **sentinel event** is defined by the Joint Commission as an unexpected occurrence involving **death or serious physical or psychological injury**, or the risk thereof. In this case, the patient experienced **asystole** and required CPR, which constitutes a serious physical injury.
- While an adverse event occurred, the **severity** and the **need for extreme medical intervention** make it a sentinel event, triggering the need for a thorough investigation.
*Active error*
- An **active error** is a mistake made by a frontline worker (e.g., administering an erroneous dose). While present in this scenario, it is a type of error, not the overarching term for the **outcome** and **severity** of the event.
- Active errors are typically the **direct cause** of an adverse event, but the question asks for the term that most accurately describes the **unexpected occurrence** and its impact.
*Near miss*
- A **near miss** is an error that could have caused harm but did not, either by chance or through timely intervention. In this case, the patient **did experience harm** (bradycardia, asystole, CPR), so it is not a near miss.
*Latent error*
- A **latent error** is a hidden flaw in a system or process that does not immediately lead to an accident but creates the conditions for one. Examples include poor system design, inadequate training, or insufficient resources.
- While latent errors might have contributed to the erroneous dose being given, this term describes the **underlying systemic problems**, not the acute, serious patient outcome.
*Adverse event*
- An **adverse event** is any injury caused by medical management rather than the underlying disease. The patient indeed suffered an adverse event.
- However, **sentinel event** is a more specific and accurate term given the **extreme severity** (asystole, CPR) of the outcome, distinguishing it from less severe adverse events.
Pharmacovigilance principles US Medical PG Question 6: A research team is studying the effects of a novel drug that was discovered to treat type 2 diabetes. In order to learn more about its effects, they follow patients who are currently taking the drug and determine whether there are adverse effects that exceed anticipated levels and may therefore be drug-related. They discover that the drug causes an excess of sudden cardiac death in 19 patients with renal failure out of 2 million total patients that are followed. Based on these results, an additional warning about this serious adverse effect is added to the investigator brochure for the drug. Which of the following clinical phase studies does this study most likely describe?
- A. Phase IV (Correct Answer)
- B. Phase II
- C. Phase V
- D. Phase III
- E. Phase I
Pharmacovigilance principles Explanation: ***Phase IV***
- This study occurs **after a drug has been approved and marketed**, focusing on post-marketing surveillance for long-term safety, effectiveness, and real-world side effects in a large and diverse patient population.
- The discovery of a rare but serious adverse effect (sudden cardiac death) in a large patient population (2 million) after the drug is already in use is characteristic of a **Phase IV clinical trial**.
*Phase II*
- Phase II trials involve a **larger group of patients (hundreds)** and focus on evaluating the drug's effectiveness and further assessing safety in patients with the target condition.
- This phase is typically conducted **before widespread marketing** and would not involve 2 million patients.
*Phase V*
- There is **no widely recognized "Phase V"** in standard clinical trial terminology (Phases I-IV focus on drug development and post-marketing surveillance).
- This term is sometimes used informally to refer to **health economics and outcomes research** or implementation studies, which are not described in the scenario.
*Phase III*
- Phase III trials are large-scale studies involving **thousands of patients** to confirm effectiveness, monitor side effects, compare the drug to standard treatments, and collect information for safe use.
- While large, these trials are conducted **before regulatory approval** and marketing, and would not typically follow 2 million patients already taking the drug in the real world.
*Phase I*
- Phase I trials are the **first stage of human testing**, involving a small group of healthy volunteers (20-100) to assess safety, dosage, and pharmacokinetics.
- The primary goal is to determine if the drug is safe enough for further testing, not to identify rare adverse events in a large patient population.
Pharmacovigilance principles US Medical PG Question 7: An experimental new drug (SD27C) is being studied. This novel drug delivers insulin via the intranasal route. Consent is obtained from participants who are diabetic and are taking insulin as their current treatment regimen to participate in a clinical trial. 500 patients consent and are divided into 2 groups, and a double-blind clinical trial was conducted. One group received the new formulation (SD27C), while the second group received regular insulin via subcutaneous injection. The results showed that the treatment outcomes in both groups are the same. SD27C is currently under investigation in which phase of the clinical trial?
- A. Phase II
- B. Phase III (Correct Answer)
- C. Post-market surveillance
- D. Phase I
- E. Phase IV
Pharmacovigilance principles Explanation: ***Phase III***
- **Phase III trials** involve a large number of participants (hundreds to thousands) and compare the new drug to standard treatment or placebo to assess its **efficacy** and monitor for adverse effects.
- The description of a **double-blind clinical trial** with 500 patients divided into two groups, comparing the new drug (SD27C) to regular insulin with similar treatment outcomes, is characteristic of a Phase III study.
*Phase II*
- **Phase II trials** typically involve a smaller group of patients (tens to a few hundred) to evaluate the drug's **effectiveness**, further assess safety, and determine the optimal dosage.
- The sample size of 500 patients in this scenario is too large for a typical Phase II trial.
*Post-market surveillance*
- This term is synonymous with **Phase IV trials**, which occur after the drug has been approved and marketed, focusing on long-term safety and effectiveness in a broader population.
- The drug is still "under investigation" and being compared to existing treatment, indicating it has not yet been approved.
*Phase I*
- **Phase I trials** are the initial human trials, usually involving a small number of **healthy volunteers**, to evaluate the drug's safety, dosage range, and pharmacokinetics.
- The study involves diabetic patients, not healthy volunteers, and the focus is on efficacy comparison, not just basic safety.
*Phase IV*
- **Phase IV trials** (or post-market surveillance) take place **after a drug has been approved** and marketed, monitoring its long-term effects, optimal use, and safety in a real-world setting.
- The drug is still in a comparative efficacy trial and has not yet received approval for general use.
Pharmacovigilance principles US Medical PG Question 8: A 21-year-old man presents to the office for a follow-up visit. He was recently diagnosed with type 1 diabetes mellitus after being hospitalized for diabetic ketoacidosis following a respiratory infection. He is here today to discuss treatment options available for his condition. The doctor mentions a recent study in which researchers have developed a new version of the insulin pump that appears efficacious in type 1 diabetics. They are currently comparing it to insulin injection therapy. This new pump is not yet available, but it looks very promising. At what stage of clinical trials is this current treatment most likely at?
- A. Phase 0
- B. Phase 2
- C. Phase 3 (Correct Answer)
- D. Phase 1
- E. Phase 4
Pharmacovigilance principles Explanation: ***Phase 3***
- **Phase 3 trials** involve large-scale studies comparing the new treatment to standard therapy or placebo, often across multiple centers.
- The scenario describes a "new version of the insulin pump" being compared to "insulin injection therapy," indicating a definitive comparison for efficacy and safety against existing treatments.
*Phase 0*
- **Phase 0 trials** are exploratory, small-scale studies (10-15 subjects) using micro-doses to gather preliminary data on pharmacodynamics and pharmacokinetics, not efficacy comparisons.
- They are typically conducted very early in drug development, examining if the drug behaves as expected in humans.
*Phase 2*
- **Phase 2 trials** evaluate the efficacy and further assess safety of a new treatment in a larger group of patients (tens to hundreds).
- While they assess efficacy, they usually don't involve direct comparison with an established standard therapy on the scale implied by the question, which is typically reserved for Phase 3.
*Phase 1*
- **Phase 1 trials** primarily focus on safety, dosage, and side effects in a small group of healthy volunteers or patients with the condition (20-100 subjects).
- These trials are not designed to assess a treatment's efficacy against an existing therapy.
*Phase 4*
- **Phase 4 trials** occur after a drug or device has been approved and marketed, focusing on long-term safety, effectiveness in diverse populations, and new indications.
- The described pump "is not yet available," indicating it has not reached the market and thus is not in Phase 4.
Pharmacovigilance principles US Medical PG Question 9: A 70-year-old man with Parkinson disease controlled on levodopa/carbidopa for 5 years develops psychotic symptoms. His neurologist considers adding an antipsychotic but is concerned about worsening parkinsonism. His family reports he has good motor control currently but the hallucinations are distressing. Evaluate the most appropriate antipsychotic choice considering the drug interaction profile.
- A. Haloperidol, as first-generation antipsychotics are most effective for psychosis
- B. Risperidone, using the lowest effective dose to minimize motor effects
- C. Quetiapine or clozapine, as they have minimal dopamine D2 receptor blockade in the nigrostriatal pathway (Correct Answer)
- D. Olanzapine, which has moderate D2 blockade balancing efficacy and side effects
- E. Aripiprazole, as a partial dopamine agonist will not worsen parkinsonism
Pharmacovigilance principles Explanation: ***Quetiapine or clozapine, as they have minimal dopamine D2 receptor blockade in the nigrostriatal pathway***
- These specific **atypical antipsychotics** have very low affinity for **D2 receptors** and rapid dissociation rates, which preserves motor function in the **nigrostriatal pathway**.
- **Quetiapine** is generally the first-line choice for **Parkinson disease psychosis** due to its safety profile, while **clozapine** is highly effective but requires monitoring for **agranulocytosis**.
*Haloperidol, as first-generation antipsychotics are most effective for psychosis*
- **Haloperidol** is a potent **D2 receptor antagonist** that significantly worsens motor symptoms in Parkinson disease by blocking remaining dopamine activity.
- It carries a high risk of inducing **extrapyramidal symptoms (EPS)** and should be strictly avoided in patients with movement disorders.
*Risperidone, using the lowest effective dose to minimize motor effects*
- Even at low doses, **risperidone** often exhibits enough **D2 blockade** to exacerbate tremor and bradykinesia in Parkinson patients.
- It has a higher propensity for causing **dose-dependent parkinsonism** compared to quetiapine or clozapine.
*Olanzapine, which has moderate D2 blockade balancing efficacy and side effects*
- **Olanzapine** has been shown in clinical trials to worsen Parkinson motor symptoms without providing superior efficacy for **hallucinations**.
- Its **moderate D2 occupancy** is still high enough to interfere with the therapeutic goals of **Levodopa** therapy.
*Aripiprazole, as a partial dopamine agonist will not worsen parkinsonism*
- Although it is a **partial agonist**, its high binding affinity allows it to act as a functional antagonist in the presence of existing **dopaminergic therapy**.
- Clinical evidence suggests **aripiprazole** can paradoxically worsen parkinsonian features and is not recommended for this patient population.
Pharmacovigilance principles US Medical PG Question 10: A 35-year-old woman taking combined oral contraceptives for 2 years develops a breakthrough seizure. She is started on carbamazepine for newly diagnosed epilepsy. Four weeks later, she presents with irregular vaginal bleeding and is concerned about contraceptive failure. Apply pharmacological principles to explain the most appropriate management.
- A. Reassure that breakthrough bleeding is normal with carbamazepine and continue current contraception
- B. Switch to higher-dose oral contraceptives or alternative contraception due to enzyme induction (Correct Answer)
- C. Discontinue carbamazepine and choose a non-enzyme-inducing antiepileptic
- D. Add supplemental estrogen to the current contraceptive regimen
- E. Perform pregnancy test and continue current medications if negative
Pharmacovigilance principles Explanation: ***Switch to higher-dose oral contraceptives or alternative contraception due to enzyme induction***
- **Carbamazepine** is a potent **inducer of cytochrome P450 enzymes (CYP3A4)**, which significantly accelerates the metabolism of estrogen and progestogen components in oral contraceptives.
- The resulting **reduced serum levels** of hormones lead to breakthrough bleeding and a high risk of **unintended pregnancy**, necessitating a more robust contraceptive strategy.
*Reassure that breakthrough bleeding is normal with carbamazepine and continue current contraception*
- Breakthrough bleeding in this context is a clinical sign of **sub-therapeutic hormone levels**, not a benign side effect of carbamazepine itself.
- Failing to adjust the regimen leaves the patient at significant **risk of contraceptive failure** due to the drug interaction.
*Discontinue carbamazepine and choose a non-enzyme-inducing antiepileptic*
- While switching to agents like **levetiracetam** is possible, carbamazepine might already be effective for her **seizure control**, and pharmacological management can often be handled by adjusting the contraceptive method instead.
- Abruptly discontinuing an effective **antiepileptic drug (AED)** can provoke withdrawal seizures or **status epilepticus**.
*Add supplemental estrogen to the current contraceptive regimen*
- Simply adding supplemental doses of estrogen is not standardized and does not address the **accelerated metabolism** of the progestogen component, which is vital for contraception.
- Standard guidelines recommend using a higher-dose **combined pill (at least 50mcg ethinylestradiol)** or switching to a method unaffected by induction, such as a **copper IUD**.
*Perform pregnancy test and continue current medications if negative*
- Testing for pregnancy is appropriate for evaluation, but continuing the current medications without changes fails to address the ongoing **pharmacokinetic interaction**.
- Continuing the same regimen ensures that the **efficacy of the oral contraceptive** remains compromised, leading to a high probability of future failure.
More Pharmacovigilance principles US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
